ACW — Actinogen Medical Share Price
Last Trade - 00:00- AU$121.87m
- AU$109.30m
- AU$0.05m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 30th Jun | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.2 | 0.16 | 0.09 | 0.2 | 0.09 | 3 | n/a | 13.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Actinogen Medical Limited, formerly Actinogen Limited, is a clinical-stage biotechnology company. The Company focuses on the treatment of Alzheimer's disease and age-related neurodegenerative diseases. The Company is engaged in treating cognitive impairment in chronic neurodegenerative diseases through the inhibition of cortisol production. The Company's Xanamem is a drug under development for the treatment of Alzheimer's disease, which is designed to block the production of cortisol in the brain. Xanamem's mechanism of action is to block the activity of a specific enzyme in the brain, the 11B-HSD1 enzyme. It focuses on Xanamem in the clinical areas, including Diabetes-Cognitive dysfunction, Cognitive dysfunction in Parkinson's Disease, Post Traumatic Stress Disorder (PTSD), Cognitive dysfunction in schizophrenia and depression, and Cardiovascular disease-Post myocardial infarction. It focuses on Phase II XanADu efficacy and safety study with mild Alzheimer's disease patients.
Directors
- Geoffrey Brooke NEC
- Steven Gourlay CEO
- Jeff Carter (59)
- Peter Webse
- Malcolm McComas (63)
- George Morstyn (70)
- Last Annual
- June 30th, 2020
- Last Interim
- December 31st, 2020
- Incorporated
- March 26th, 1999
- Public Since
- October 12th, 2007
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 1,450,787,169
- Address
- Select House, SYDNEY, 2000
- Web
- http://actinogen.com.au/
- Phone
- +61 289647401
- Auditors
- Ernst & Young
Latest News for ACW
Upcoming events for ACW
Full Year 2021 Actinogen Medical Ltd Earnings Release
Actinogen Medical Ltd Annual Shareholders Meeting
Similar to ACW
ADALTA ORD
Australian Stock Exchange - SEATS
ALTERITY THERAPEUTICS ORD
Australian Stock Exchange - SEATS
ANATARA LIFESCIENCES ORD
Australian Stock Exchange - SEATS
ANTEOTECH ORD
Australian Stock Exchange - SEATS
ARGENICA THERAPEUTICS ORD
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:55 UTC, shares in Actinogen Medical are trading at AU$0.08. This share price information is delayed by 15 minutes.
Shares in Actinogen Medical last closed at AU$0.08 and the price had moved by +257.14% over the past 365 days. In terms of relative price strength the Actinogen Medical share price has outperformed the ASX All Ordinaries Index by +182.93% over the past year.
There is no consensus recommendation for this security.
Actinogen Medical does not currently pay a dividend.
Actinogen Medical does not currently pay a dividend.
Actinogen Medical does not currently pay a dividend.
To buy shares in Actinogen Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.08, shares in Actinogen Medical had a market capitalisation of AU$121.87m.
Here are the trading details for Actinogen Medical:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: ACW
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Actinogen Medical does not currently have a style classification.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Actinogen Medical. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +232.92%.
As of the last closing price of AU$0.08, shares in Actinogen Medical were trading +45.73% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Actinogen Medical.
Actinogen Medical's management team is headed by:
- Geoffrey Brooke - NEC
- Steven Gourlay - CEO
- Jeff Carter -
- Peter Webse -
- Malcolm McComas -
- George Morstyn -
We do not have data on Actinogen Medical's shareholders